Acute myeloid leukemia (AML) with the Internal Tandem Duplication (ITD) mutation of the FMS-like tyrosine kinase 3 gene (FLT3-ITD) remains, to this day, one of the greatest challenges of modern hematology due to poor prognosis despite allogeneic hematopoietic stem cell transplantation (allo-HCT). This evidence concerns the gene FLT3 and acute myeloid leukemia.